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Abstract 
Human papillomaviruses (HPVs) are a necessary cause of carcinoma of the cervix and other 
mucosal epithelia. Key events in high-risk HPV (HRHPV)-associated neoplastic progression 
include persistent infection, deregulated expression of virus early genes in basal epithelial 
cells and genomic instability causing secondary host genomic imbalances. There are multiple 
mechanisms by which deregulated virus early gene expression may be achieved. Integration 
of virus DNA into host chromosomes is observed in the majority of cervical squamous cell 
carcinomas (SCC), although in ~15% of cases the virus remains extra-chromosomal 
(episomal). Interestingly, not all integration events provide a growth advantage to basal 
cervical epithelial cells, nor lead to increased levels of the virus oncogenes E6 and E7, when 
compared with episome-containing basal cells. The factors that provide a competitive 
advantage to some integrants, but not others, are complex and include virus and host 
contributions. Gene expression from integrated and episomal HRHPV is regulated through 
host epigenetic mechanisms affecting the virus long control region (LCR), which appear to be 
of functional importance. New approaches to treating HRHPV-associated mucosal neoplasia 
include knockout of integrated HRHPV DNA, depletion of virus transcripts and inhibition of 
virus early gene transcription through targeting or use of epigenetic modifiers. 
 
Keywords: Human papillomavirus; mucosa; oncogene; E6/E7; epigenetics; integration; 
squamous cell carcinoma 
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Human papillomavirus infection and global disease 
Human papillomavirus (HPV) infection poses a significant risk to morbidity and mortality 
worldwide, being associated with ~4.8% of all human cancers [1]. Papillomaviruses are a 
family of small, non-enveloped viruses with a double-stranded DNA (dsDNA) genome of, in 
the case of human papillomavirus (HPV), approximately 7.9 kilobases (kb) [2]. To date, over 
180 individual types of HPV have been sequenced [3, 4] and all infect epithelial cells, usually 
with a preference for either cutaneous or mucosal surfaces. The proportion that infects the 
genital tract (30-40 types from the alpha genus) can be sub-divided into low and high-risk 
types, based on their oncogenic potential. Low-risk HPV types, including HPV6 and 11, are 
associated more with benign ano-genital warts or condylomata, whereas at least twelve high-
risk HPV (HRHPV) types, HPV16, 18, 31, 33, 35, 39, 45, 51 52, 56, 58 and 59, are 
associated with ano-genital cancers and precursor neoplastic lesions [5, 6]. 
 
Although HPV infection is nearly ubiquitous, the virus does not cause cancer in the large 
majority of cases [7]. Most infections are inapparent and cleared by the host immune system 
within 18 months [8]. However, ~10-15% of women do not clear HPV infection, with 
persistence of high-risk HPV being the major risk factor for development of ano-genital 
cancers [9, 10]. 
 
The life cycle of HPV 
In stratified epithelia HPV infects cells in the basal layer, most likely via epithelial wounding 
or micro-fissures [11], through an entry mechanism that is thought to require active cell 
division [12, 13]. The cervical transformation zone at the squamo-columnar junction may be 
susceptible to malignancy due to the heightened accessibility of epithelial reserve cells or 
stem cells in this region [14, 15]. The ability of HPV to target basal stem cells is also likely to 
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provide one mechanism by which persistent infection is established in some individuals 
(Figure 1) [16]. 
 
Initial infection of basal cells is usually associated with low level amplification of the HPV 
episome, to a copy number of ~100 per cell. The concerted expression of virus early genes E1 
(virus DNA helicase) and E2 (virus transcription factor and genome tether) allow replication 
of virus DNA from the origin (Figure 2) [17, 18]. Virus copy number is then maintained 
within the basal proliferating compartment of the epithelium, with the E2 protein, in 
conjunction with various host binding partners, directing partitioning of virus genomes via 
tethering to the host chromosomes [19-21]. This maintenance phase of the virus life cycle 
also involves expression of the oncoproteins E6 and E7 from the virus early promoter (p97 in 
the major HRHPV, HPV16) [22, 23]. HPV E6 and E7 interact with various host proteins and 
carry out many modulatory functions within the infected cell (Figure 3) [24]. The constrained 
level to which E6 and E7 proteins are expressed in basal cells is likely to aid immune evasion 
and ultimately persistence of infection in the host [16]. 
 
During the HPV life cycle, the programme of virus gene expression is dependent on the 
differentiation profile of the infected cells (Figure 1). HPV proteins are able to drive 
differentiating suprabasal squamous epithelial cells back into the cell cycle, in order to 
reactivate DNA synthesis and thereby maintain an elevated virus genome copy number [25, 
26]. Virus RNA splicing shifts from early to late polyadenylation sites, controlled by E2 and 
the availability of splicing factors, which are variably expressed according to the 
differentiation state of the infected cell [27, 28]. Similar mechanisms are responsible for the 
production of late gene products L1 and L2, the virus capsid proteins, in the superficial cell 
layers [29]. The productive life cycle is completed when virions self-assemble, package their 
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replicated genomes and are released non-lytically from the cell into the immediate external 
environment [26].  
 
Cervical cancer: the paradigm of HPV-associated oncogenesis  
HPV has been determined as a definite risk factor for numerous human cancers of mucosal 
surfaces, including penile, vulval, vaginal, anal, oropharyngeal and cervical carcinomas [1, 2, 
6]. Cervical cancer is the fourth most common malignancy in women worldwide, with ~528K 
cases (~12% of all female cancers) and ~266K deaths (~50% of cases) per annum [6]. 
 
The majority of cervical cancers represent squamous cell carcinomas (SCCs), although 
adenocarcinomas and adeno-squamous carcinomas are also seen. SCCs arise from precursor 
lesions that may be classified using the three-tier cervical intraepithelial neoplasia (CIN) or 
two-tier squamous intraepithelial lesion (SIL) systems [30]. Low-grade SILs (LSILs) broadly 
correspond to CIN1 and generally represent non-neoplastic productive HPV infections that 
have a low risk of progression to malignancy [31]. In contrast, high-grade SILs (HSILs), 
broadly corresponding to CIN2/3, comprise abortive virus infections in which there is 
deregulated expression of HPV early genes in basal epithelial cells and a greater risk of 
progression to invasive disease (Figure 1) [32]. The cervical squamous cell carcinomas 
(SCCs) that arise from these precursor SILs are usually clonal, due to the emergence of cells 
with the greatest competitive growth advantage [33, 34].  
 
Deregulation of HPV oncogene expression in neoplastic progression 
An important event in HPV-associated neoplastic progression is deregulation of normal 
patterns of virus gene expression. Increased expression of E6 and E7 in basal epithelium 
leads to pro-malignant effects in the proliferating cell compartment, resulting in increased 
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cell cycle entry [35] and loss of differentiation across the epithelium [36]. There appear to be 
multiple causes of deregulated HPV gene expression, occurring at both genetic and 
epigenetic levels. The most common event in cervical SCC is integration of the virus genome 
into host chromosomes (Figure 2) [36]. However, a proportion of cervical SCCs are 
associated with retention of episomes, in which the E2 open reading frame is maintained and 
expressed throughout progression to malignancy [37].  
 
HRHPV integration 
In cervical SCC tissue samples, ~50-80% of HPV16-positive and almost all HPV18-positive 
cases are associated with integration of virus genomes [38-42]. Interestingly, different HPV 
types appear to integrate at different frequencies. In one study of 835 cervical samples, 
integration was detected in 55% of HPV16-positive cases, 92% of HPV18-positive cases, 
14% of HPV31-positive cases, 37% of HPV33-positive cases and 83% of HPV45-positive 
cases [41]. The frequency of HPV integration in SILs has been widely debated. It has been 
proposed that integration can either be an early event associated with LSIL to HSIL 
progression [43-46] or a later event that accompanies progression from HSIL to SCC [47, 
48].  
 
Such contrasting perspectives can at least partly be explained by technical differences 
between the methods used to identify integrated HPV. Protocols designed to detect virus-host 
fusion transcripts, such as RNA in situ hybridisation (ISH) [49] or 3’ RACE-PCR (termed 
amplification of papillomavirus oncogene transcripts (APOT)) [50] will only identify 
transcriptionally active integrants. However, methods that target the virus DNA, including 
DNA ISH [47, 51, 52], Southern blotting [38, 53], restriction-site PCR [54] and quantitative 
PCR [44, 55], will detect all integrated virus genomes, regardless of their transcriptional 
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activity [56]. Previous in vitro studies have suggested that HPV integration events occur in 
cells that initially retain non-integrated episomes. Expression of the virus E2 transcriptional 
regulator from such episomes is able to repress integrant-derived transcription [57, 58]. 
Episome clearance (for example, through a host anti-virus response) [59] is an important step 
in overcoming this transcriptional inhibition and represents a key additional step in cervical 
neoplastic progression following initial virus integration. Accordingly, identification of 
integrated virus DNA does not necessarily indicate transcriptionally active, and therefore 
selected, integration events, for which RNA-based detection methods are required. 
 
In cervical SCCs, HRHPV may integrate as a single copy or as multiple copies. In the former 
(so called type-I integrants), complete loss or truncation of the virus early 3' region leads to 
deletion or disruption of integrant-derived E2, together with loss of the virus early gene 
polyadenylation site [36]. Thus, the transcribing polymerase adopts the nearest host 
polyadenylation site, producing virus-host fusion transcripts thought to be more stable than 
those of the virus alone. In the cells that undergo selection during cervical carcinogenesis, 
these changes lead to increased expression and stability of transcripts encoding HRHPV E6 
and E7 [34, 60]. The second type of integrant (type-II integrants) involves concatemers of full 
length HPV (including the E2 gene), often with interspersed host sequences. In cells 
containing multiple integrated HPV copies, there appears to be selection of cells containing 
only a few transcriptionally active sites [49]. In concatemerised virus DNA, epigenetic 
silencing of full length copies, for example through DNA methylation, would prevent E2 
expression [61], with transcription being limited to the virus-host junction sequences where 
the E2 gene is disrupted or deleted. Such epigenetic regulation could also restrict E6 and E7 
transcription, to prevent deleterious genomic instability caused by high-level gene expression 
[37, 49]. 
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Until recently, it has been unclear whether all integration events, when de-repressed following 
episome loss, lead to increased levels of virus oncogenes and/or a cell growth advantage. 
Selection of integrated HRHPV occurs relatively early in cervical carcinogenesis and 
determinants of selection have been difficult to investigate adequately using clinical samples 
[36]. However, the W12 model of HPV16-associated cervical carcinogenesis has enabled the 
generation of a useful panel of cell clones that were derived from an identical background 
under non-competitive conditions and differed only by the genomic site of HPV16 integration 
[62]. Interestingly, when compared with the episome-containing cells from which they were 
generated, only ~50% of these clones showed significantly greater growth rates and only 
~50% showed significantly greater expression of E6/E7 [63], indicating that HRHPV 
integration per se does not necessarily lead to increased oncogene expression or a cell growth 
advantage. It remains unclear what provides some virus integrants with a selective advantage 
compared with others, although the epigenetic environment at the integrated virus LCR, and a 
contribution from host genes appear to be involved [63]. Interestingly, the site of virus 
integration in the host genome may also affect cell responsiveness to steroid hormones [64-
67], through as yet unidentified mechanisms. 
 
A large majority of HRHPV integration sites in cervical SCC have been mapped at, or near 
to, chromosome fragile sites (CFS), with around 50% of selected HPV16 and HPV18 
integration sites found in the same chromosomal band as a CFS [62, 68]. The E6/E7 proteins 
are likely to play a role in the process of integration [69], although major genomic instability 
is typically seen following the emergence of intergant-containing cells [70, 71]. While 
HRHPV integration sites are widely distributed across the human genome, it appears that 
integration is more likely to occur at certain genomic sites (so-called integration hotspots), 
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such as 3q28, 4q13.3, 8q24.21, 13q22.1 and 17q21 [54, 62, 72, 73]. Some integration sites 
share sequence homology with the HPV16 genome, most commonly with the E5 and L2 
genes, albeit only around 50 nucleotides maximally [73]. HPV integration sites also have a 
propensity for occurring near to clusters of host microRNAs (miRNAs). In one study, over 
two thirds of integrants mapped within 3MB of a miRNA-coding locus, potentially leading to 
deregulation of miRNA expression [73]. It has been proposed that the mechanism by which 
HPV genomes are tethered onto host chromosomes, involving interaction of the E2:Brd4 
complex with acetylated histones that are found most commonly at active sites of 
transcription or CFSs, allows HPV genomes to integrate more often at CFS when genomic 
instability increases [74].  
 
As well as the question of whether integration of HPV genomes at particular host sites can 
lead to specific changes in virus gene expression, there is contention as to whether integration 
can lead to insertional mutagenesis of host genes, possibly leading to greater selectability of 
the affected cells. Early work assessing HPV integration sites in cervical cancers found 
evidence for insertion at sites of both host tumour suppressor genes and host oncogenes [75-
77]. There have been reports of repeated integration, for example near to the MYC gene at 
8q24 [77-79]. Recent genome-wide studies of HPV-positive cell lines and tumour material 
that have led to a much greater insight into the extent of amplification of virus sequences and 
local rearrangement of host DNA at sites of integration [80-82]. Significant changes in 
expression of genes at HPV integration sites were suggested from genome wide cross-
sectional studies of cervical carcinomas [83, 84]. Despite other evidence supporting potential 
HPV insertional mutagenesis in ano-genital neoplasia [56, 85-87], it should be noted that 
there are few functional data that support this possibility, and thus no causal association with 
cervical carcinogenesis has been verified. Indeed, a recent study of oropharyngeal SCC 
Page 13 of 32
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
10 
 
(OSCC) found that integration of HPV16 genomes had no significant effect on the expression 
of virus-disrupted host genes [88].  
 
Epigenetic modification of the HPV LCR: DNA methylation 
Deregulation of HPV oncogene expression under conditions of episome maintenance may 
occur via diverse mechanisms [37]. There are reports of mutations to the LCR of episomes, 
which modify the interaction of several transcription factors and result in altered virus 
transcript levels [89-92]. However, the relationship of these changes with clinical disease is 
still poorly defined. Of greater importance may be epigenetic changes affecting the virus 
LCR (Figure 4). 
 
One mechanism of abrogating binding of the virus regulatory protein E2 to the episomal or 
integrated HPV genome is methylation of CpG dinucleotides within the E2 binding sites 
(E2BSs) of the LCR [93]. However, a clear association between DNA methylation of the 
LCR and disease progression is still not resolved. While it was initially suggested that DNA 
methylation at the LCR decreased with progression from normal cervix to SILs and SCC 
following HPV16 infection [94-97], other studies have shown that increases in LCR DNA 
methylation can occur [98-100]. There are further discrepancies across studies that focussed 
on the E2BSs in the LCR, when considering both disease progression and cell differentiation. 
In cells showing episome maintenance, E2BSs of genomes in a basal-like monolayer culture 
showed high levels of methylation that were lost during cell differentiation [101, 102]. 
However one study, while also showing such differentiation-related reductions at the 
promoter-distal E2BS, showed an increase in DNA methylation at the three promoter-
proximal E2BSs (Figure 4) [103], changes that may facilitate episome replication in 
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differentiated cells. For integrated virus genomes there is little DNA methylation at the LCR 
unless multiple copies have integrated concatemerically [61]. 
 
Epigenetic modification of the HPV LCR: chromatin modification 
Gene expression from virus genomes, both episomal and integrated, is also associated with 
post-translational modifications to histone tails of nucleosomes at the HPV LCR, and with 
subsequent transcription factor occupancy. The association of nucleosomes with the HPV 
genome, whether episomal [104] or integrated [105], has been known for nearly forty years. 
Functional association of histone proteins with the HPV LCR was shown to occur at the 
enhancer and early promoter (Figure 4), depending on specific DNA sequences, such that 
nucleosome occupancy appeared distinct for different HPV types [106]. Further evidence 
from the use of histone deacetylase (HDAC) inhibitors, which caused increased levels of 
early transcripts, pointed towards modification of episome-associated histones and 
nucleosome remodelling as a method of virus transcriptional regulation [107]. This early 
finding has been verified by work showing the necessary involvement of some histone 
acetyltransferases (HATs), including p300, in efficient activation of HPV gene expression 
[108, 109] and the presence of acetylated histones H3 and H4 (H3ac and H4ac, respectively) 
at the LCR in transcriptionally active episomal [37, 110] and integrated HPV genomes [63]. 
Consistent with these observations, the recruitment of HDACs by various host proteins is 
able to repress HPV transcription [111, 112].  
 
The level of association of histone post-translational modifications at the LCR in cervical 
squamous cells has been shown to change as cells differentiate and as disease progresses. 
Upon cell differentiation, activation of virus late gene expression is associated with 
stimulation of the late promoter (Figure 4), coinciding with increases in levels of the active 
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marks H3ac and dimethylated lysine 4 of H3 (H3K4me2) and with increased transcription 
factor binding at the enhancer and promoter [110, 113]. Throughout the course of in vitro 
neoplastic progression associated with episomal HPV16, H3ac and H4ac were present at the 
virus enhancer and at both early and late promoters [37]. Acetylation of histones initially 
increased across the HPV16 genome as the cells progressed phenotypically to SCC, subsiding 
in association with decreasing oncogene expression in late-stage cells (a change capable of 
limiting excessive genomic instability) [37]. In cells containing integrated HPV16, high 
levels of virus transcription per DNA template were associated with greater abundance of 
marks of active transcription, H3ac and H3K4me3 across the LCR and early gene open 
reading frames [63], together with reduced association of H3K9me2 and H3K27me2. The 
latter are marks of transcriptional repression that have also been observed at the numerous 
heterochromatinised genomes in CaSki cervical SCC cells [114].  
 
Together, these data indicate that levels of HPV16 oncogene transcription in cervical 
squamous cells are directly associated with chromatin structure at the HPV LCR and 
promoters. Such findings are consistent with published ChIP-seq data of histone 
modifications observed in populations of HPV18 integrant containing HeLa cervical 
adenocarcinoma cells [115]. Strikingly, assessment of transcription factor association across 
the HPV18 genome in HeLa showed binding of all interacting proteins at the LCR. Despite 
the length of the LCR and the presence of known binding motifs, it is unlikely that all 
transcription factors can bind this region at the same time; hence the associations would be 
dynamic [115]. Furthermore, it is possible that transcription factor binding might not occur in 
a regulated, sequence specific manner, at least in HeLa cells. This is supported by the finding 
that certain specific locations in the human genome, known as high-occupancy target (HOT) 
regions and first found in C. elegans, are able to bind numerous unrelated transcription 
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factors [116]. Importantly, such regions have been found in HeLa cells [117], although the 
relevance for the integrated virus genome has not yet been demonstrated. It has been 
proposed that a majority of transcription factors could be recruited to the HOT regions by a 
fewer number of common co-factors, thus allowing the possibility of some sequence-specific 
transcription factor binding. It will therefore be interesting to establish how numerous 
transcription factors are able to bind a relatively short genomic regulatory sequence like the 
virus LCR and whether there is any biological relevance to these associations, for example 
during differentiation of HPV-infected cells.  
  
Genetic and epigenetic modification of host genes 
Chromatin modification and DNA methylation. In addition to the above host effects on 
HPV transcription, HRHPV oncoproteins are able to modify host gene transcription through 
epigenetic mechanisms. The E7 protein interacts with and inhibits polycomb group proteins, 
which act in concert to repress gene expression [118, 119]. In conjunction with E7-mediated 
up-regulation of lysine demethylases (KDM) 6A and 6B, which remove the facultative 
heterochromatin mark H3K27me3, inactivation of the polycomb repressive complex 2 
(PRC2) histone methyltransferase EZH2 and down-regulation of PRC1 protein BMI1 by 
HRHPV proteins are able to cause reactivation of transcription from numerous normally 
repressed genes, including members of the HOX group and the cyclin-dependent kinase 
inhibitor p16INK4A [120, 121]. Interestingly, in SCCs HPV16 has also been shown to 
decrease the level of RBBP4 (RbAp48) [122], a nucleosome-binding recruitment protein for 
PRC2 and HDAC containing complexes including NuRD, Sin3 and CoREST, thereby further 
indirectly modulating global host gene expression. Additionally, E7 is able to bind and 
sequester HDACs allowing both transcriptional activation of target genes, such as that 
mediated by the normally HDAC-repressed transcription factor HIF1α [123], and repression 
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of immune genes such as TLR9 via retargeting of deacetylase (HDAC1) and demethylase 
(JARID1B) enzymes [124]. Indeed, E7 was first shown to gain HDAC activity through 
interaction with Mi-2 (CHD4), a member of the nucleosome remodelling deacetylase (NuRD) 
complex, thus promoting growth of HPV infected cells [125]. Furthermore, E7 can bind 
chromatin remodelling enzyme BRG1 (SMARCA4) and, alongside gained HDAC activity, 
repress host gene promoters including that of C-FOS, in contrast to the activating effect of 
BRG1 at the integrated HPV18 LCR [126-128]. The HPV oncoproteins, especially E7, 
therefore balance a global cellular inhibition of chromatin modification complexes by 
retargeting enzymatic activity toward specific host genes, probably including the virus 
genome, to initiate and maintain infection of keratinocytes. 
 
Of possible clinical significance has been the accumulation of data showing changes in host 
gene DNA methylation throughout the progression of HPV-associated disease. High-risk 
HPV types have been associated with up-regulation at the protein level of DNA 
methyltransferases (DNMTs) 1, 3A and 3B [129-132]. The overall effect, whether direct or 
indirect, is an increase in DNA methylation of the host genome, often occurring at tumour 
suppressor genes and inhibiting their transcription. Studies have led to numerous potential 
biomarkers of disease progression that may in due course prove clinically useful [133, 134]. 
 
Host DNA mutations. In HPV-associated SCCs, deregulation of virus gene expression is 
typically associated with abnormalities of host genes, usually in a manner that activates 
oncogenes or inactivates tumour suppressor genes. Recent genome-wide next generation 
sequencing studies have allowed in-depth analysis of the frequencies and associations of 
somatic mutations in SCCs. Since HRHPV functionally inactivates p53 and pRB (Figure 3), 
relatively few examples of somatic mutations of the TP53 and RB1 genes have been found in 
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cervical SCCs (5% and 3%, respectively) [135]. Many of the most frequently mutated genes 
are associated with signalling pathways; recurrent mutations have been found in SCCs of the 
cervix and head and neck at the PIK3CA, MAPK1 and EGFR genes, with strong relationships 
between the NOTCH signalling pathway and  head and neck SCC [84, 136-138]. Other 
relatively commonly mutated genes in SCCs include CDKN2A, PTEN, HRAS and FBXW7 
[84, 136, 137]. Interestingly, a small number of mutations have now been found in genes 
encoding proteins associated with chromatin modification and remodelling, including 
repressive (EZH2) and activating (MLL2, p300) enzymes [84, 136]. Intriguingly, the ERBB2 
gene, whose encoded protein binds ligand-activated EGFR and enhances kinase-mediated 
activation of downstream signalling pathways including MAPK and PI3CA, is not just 
mutated in cervical SCCs but is also a reported site of HPV integration, with concomitant up-
regulation in gene expression [83, 84, 135]. 
 
MicroRNAs 
Post-transcriptional control of host gene expression in cervical cancer is an area of current 
interest. Cervical carcinoma is associated with changes to host microRNAs (miRNA) profiles 
[134, 139] and there are data supporting direct HPV effects on miRNA levels. Host miRNAs 
appear to be modulated by the major HRHPV oncoproteins E6 and E7 [140] and also by E5 
[141]. Together, such changes affect cell pathways associated with apoptosis, differentiation 
and proliferation [140, 142] and in turn may regulate differentiation-dependent virus gene 
expression [140]. Altered expression of host miRNAs appears to occur at an early stage in 
HPV-associated cancer development and the changes may be prove to be diagnostically 
useful [134]. Modulation may be due to chromosomal copy number alterations, either directly 
at the miRNA locus [143] or indirectly via mechanisms such as upregulation of Drosha 
expression following 5p gain [139]. Further indirect down-regulation of some miRNAs might 
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also be due to global changes in DNA methylation patterns at promoter regions in cervical 
SCCs [134], while integration of the HPV genome at miRNA loci may also be able to modify 
expression from such loci [73]. Interestingly, a small number of studies have reported the 
possible expression of HPV-encoded miRNAs that could target virus and host transcripts 
[144, 145]. However, these findings do not appear to apply across all papillomavirus types 
[146] and require further biological verification. Host and/or virus gene expression may also 
be controlled by other non-coding RNAs, although these have yet to be identified.  
 
Conclusions 
It is becoming increasingly clear from in vivo and in vitro data that there are multiple routes 
by which neoplasia develops at mucosal surfaces following HRHPV infection. Events of 
fundamental importance in these processes include virus persistence, deregulation of virus 
early gene expression and host genomic instability. Although there are prospects for 
improved control of HRHPV-related disease through vaccination, worldwide vaccine 
coverage is still very low and current vaccines target a restricted range of virus types. There 
are still important opportunities for identifying new strategies for treating HRHPV-associated 
disease. Multiple approaches are under consideration, including knockout of integrated virus 
sequences through gene editing, or depletion of virus transcripts using small interfering RNA 
(siRNA) [147, 148]. Increased understanding of epigenetic regulation of gene expression 
from episomal and integrated HRHPV DNA, and of host gene expression through effects of 
HRHPV early proteins, may allow the development of epigenetic therapies that will permit 
selective inhibition of virus transcription without deleterious host effects. The availability of 
accurate in vitro models for detailed functional characterisation of the cell selection processes 
that occur during HRHPV-associated neoplastic progression will be of value in identifying 
rational therapeutic strategies for cervical and other carcinomas. 
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Figure Legends 
 
Figure 1. HPV-associated neoplastic progression in cervical epithelium. 
HPV may infect basal squamous epithelial cells following micro-trauma or may target cells at 
or near the squamo-columnar junction (SCJ), including epithelial reserve cells. In the normal 
virus life cycle, HPV early gene expression is initiated (red nuclei) while the HPV genome is 
maintained at low copy number as an episome. As infected basal cells replicate and daughter 
cells move into the parabasal layer, expression of virus oncoproteins E6 and E7 allow cells 
that would normally differentiate to re-enter the cell cycle and produce an expanded 
epithelium. Migration of cells to the upper layers causes increased replication of the virus 
genome to high copy number, with expression of the virus E4 gene and often the structural 
proteins L1 and L2. These events allow encapsidation of the episomes into infectious virions 
which are then shed from/with the cornified surface. Such completion of the virus life cycle is 
supported in a low-grade squamous intraepithelial lesion (LSIL) but not in a high-grade SIL 
(HSIL), where disease progression is associated with deregulation of virus early gene 
expression and loss of late gene expression. Squamous cell carcinoma arises when cells gain 
the ability to penetrate the epithelial basement membrane and invade the underlying stroma. 
 
Figure 2. Physical states of the HPV16 genome. 
The left hand panel shows the genomic organisation of the major HRHPV, HPV16, 
demonstrating the early (E) region, the late (L) region and the long control region (LCR). The 
integrated forms of HPV observed in cervical neoplasia (i.e. following a selection process) 
may represent fragments of the virus genome, with retention of E6/E7 and deletion or 
disruption of E2 (type-I integrants) or may represent concatamerised full length copies (type-
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II integrants), in which transcriptional activity appears to be restricted to downstream 
sequences. (ORI = origin of replication; * = disrupted open reading frame.) 
 
Figure 3. Important functions of high- and low-risk HPV E6 and E7 proteins.  
The Figure gives an overview of important direct and indirect effects of the alpha genus HPV 
E6 and E7 proteins on cellular pathways and processes. Some of the areas of overlap and 
interplay between the functions of the two oncoproteins are shown. Important roles of E6 and 
E7 include inhibition (low-risk HPV) and degradation (high-risk HPV) of cellular p53 and 
pRb, respectively. Loss of p53 has multiple consequences (some not illustrated), including 
effects on proliferation, DNA repair, senescence and apoptosis. The diagram does not take 
account of dose dependent effects of the virus oncoproteins nor their level of expression 
throughout progression. (Red oval = general downregulation of cellular process or pathway. 
Green oval = general upregulation of cellular process or pathway. Brown oval = modulation 
of cellular process or pathway. HATs = histone acetyltransferases, including p300, CBP, 
pCAF and TIP60. CDKs = cyclin-dependent kinases.) 
 
Figure 4. The HPV16 long control region (LCR).  
The LCR is positioned between the late and early virus gene regions. The virus replication 
protein E1 binds as a dimer of hexamers at the origin of replication (ORI), while the virus 
transcription factor E2 associates as a dimer at four E2 binding sites (E2BSs) which broadly 
define the 5’, central and 3’ regions. Transcription of early genes occurs from the early 
promoter (P97) and is dictated by the binding of numerous host transcription factors and the 
virus E2 dimer across the enhancer, silencer and promoter regions. Activation of transcription 
from the late promoter (P670) is dependent upon cell differentiation and binding of 
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differentiation-associated transcription factors. (Poly(A)L = Late polyadenylation site; ORF = 
open reading frame.) 
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